News

Tibion has developed the PowerKnee, a wearable bionic device for the leg which actively and transparently supplements muscle strength. To achieve licensure, Tibion demonstrated compliance with the federal

For the fourth quarter of 2008, Pfizer posted net income of $266 million, a decline of 90% compared with the prior-year quarter, and reported diluted earnings per share

The Zoraxel Phase IIa trial is a double blind, placebo-controlled, dose ranging study conducted at three US study sites in up to 40 male subjects ages 18 to

Quarterly Results: Instrument, reagent disc and hematology reagent revenues increased by an aggregate of $1.0 million, or 4%, for the quarter ended December 31, 2008, over the same

The limited launch of these systems in Europe marks St Jude Medical’s first products in the deep brain stimulation (DBS) systems market. The Libra DBS systems function in

The payment has been triggered by the successful transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403. The

A total of 214 patients have enrolled two months ahead of schedule in the clinical study of Urgent PC versus sham effectiveness in treatment of overactive bladder symptoms

David Brennan, chief executive officer, said: “AstraZeneca has delivered a robust performance in an increasingly challenging market environment. I am particularly pleased with our continued success in globalising

“SurModics achieved record revenue and earnings for the first quarter of fiscal 2009, driven primarily by the recognition of previously deferred revenue, which was triggered by Merck’s termination